Globus Medical, Inc. (GMED): Price and Financial Metrics
Globus Medical, Inc. (GMED)
Today's Latest Price: $59.92 USD
Updated Nov 27 5:00pm
Add GMED to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
GMED Stock Summary
- Price to trailing twelve month operating cash flow for GMED is currently 34.19, higher than 87.61% of US stocks with positive operating cash flow.
- For GMED, its debt to operating expenses ratio is greater than that reported by just 0.52% of US equities we're observing.
- GMED's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.96% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Globus Medical Inc are ICUI, SSTK, CRTO, ITI, and PLPC.
- Visit GMED's SEC page to see the company's official filings. To visit the company's web site, go to www.globusmedical.com.
GMED Stock Price Chart Interactive Chart >
GMED Price/Volume Stats
| Current price | $59.92 | 52-week high | $60.17 |
| Prev. close | $59.80 | 52-week low | $33.41 |
| Day low | $59.70 | Volume | 227,917 |
| Day high | $60.03 | Avg. volume | 883,161 |
| 50-day MA | $53.71 | Dividend yield | N/A |
| 200-day MA | $50.06 | Market Cap | 5.91B |
Globus Medical, Inc. (GMED) Company Bio
Globus Medical focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company was founded in 2003 and is based in Audubon, Pennsylvania.
GMED Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $59.92 | $14.88 | -74% |
Below please find a table outlining a discounted cash flow forecast for GMED, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Globus Medical Inc ranked in the 19th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for GMED, they are:
- The company's balance sheet shows it gets 100% of its capital from equity, and 0% of its capital from debt. Notably, its equity weight is greater than 95.79% of US equities in the Healthcare sector yielding a positive free cash flow.
- The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 0.05% of the free cash flow producing stocks we're observing.
- Globus Medical Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -6.65. This coverage rate is greater than that of merely 10.8% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -75% |
| 1% | -75% |
| 2% | -74% |
| 3% | -74% |
| 4% | -74% |
| 5% | -74% |
Want more companies with a valuation profile/forecast similar to that of Globus Medical Inc? See AZN, CNC, NUVA, CNMD, and LMNX.
Loading social stream, please wait...